News | May 21, 2026
IOLCP revenue rises 11.5% YoY to Rs. 2,319.1 crore in FY26
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Ranks among the top 15% companies globally
This approval authorizes the company to export Ibuprofen to the Chinese markets
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
EDQM has also issued a Certificate of Suitability for Allopurino
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
